Difference between revisions of "Part:BBa K2812006"
MariskaBruls (Talk | contribs) m |
MariskaBruls (Talk | contribs) m |
||
| Line 15: | Line 15: | ||
<!-- --> | <!-- --> | ||
| + | |||
| + | <!-- | ||
<span class='h3bb'>Sequence and Features</span> | <span class='h3bb'>Sequence and Features</span> | ||
<partinfo>BBa_K2812006 SequenceAndFeatures</partinfo> | <partinfo>BBa_K2812006 SequenceAndFeatures</partinfo> | ||
| − | + | <!-- --> | |
<!-- Uncomment this to enable Functional Parameter display | <!-- Uncomment this to enable Functional Parameter display | ||
Revision as of 09:55, 15 October 2018
Coding sequence for Pyocin S5 with HlyA and His6-tag
Coding sequence for Pyocin S5, which is a bacteriocin produced by a specific strain of P. aeruginosa and is effective against other strains of P. aeruginosa. The sequence encodes for an effector component that consists of a receptor binding domain, a translocation domain and a killing domain. Furthermore it contains an immunity component which gives immunity against the bacteriocin. The HlyA tag is a secretion signal peptide which is used for secretion via the Type 1 secretion pathway of gram-negative bacteria. In order to facilitate protein purification, an N-terminal HIS-tag is present.
Usage and Biology
The working mechanism of Pyocin S5 involves making the target cell membrane permeable, causing leakage of intracellular materials. It has been demonstrated that is has antimicrobial activity against seven P. aeruginosa strains (DWW3, In3, In4, In7, In8, InA, and InB). P. aeruginosa PAO1, E. coli (BL21 (DE3), W3110, and ATCC15597) and S. aureus ATCC6538 were insensitive to pyocin S5. We as iGem Eindhoven 2018 aimed to use this biobrick for prevention of wound infections.